RLMDRELMADA THERAPEUTICS, INC.
- GlobeNewswire
Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND clearance.Sepranolone IND filing ...
- GlobeNewswire
Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
Brings nearly three decades of leadership spanning NMIBC, corporate strategy and business development to help advance NDV-01 and support the Company's long-term growth and value creation. CORAL GABLES, Fla., July ...
- GlobeNewswire
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for ...
- GlobeNewswire
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for ...
- Analyst Upgrades
Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call
HC Wainwright initiates Relmada Therapeutics with a Buy rating and $12 target, highlighting its bladder cancer potential. ...
- Analyst Upgrades
This Talen Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts changed outlook on top Wall Street names. See all changes on our analyst ratings page. Check out analysts' views on TRNO, RLMD, TLN, IMMX, CEG. ...
- Analyst Upgrades
HC Wainwright & Co. Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $12
HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Relmada Therapeutics with a Buy rating and announces Price Target of $12. ...
- GlobeNewswire
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada's sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics. CORAL GABLES, ...
- GlobeNewswire
Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference
CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central ...
- GlobeNewswire
Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at ...
- GlobeNewswire
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central ...
- GlobeNewswire
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026
12-Month Phase 2 data in High-Risk NMIBC to be presented Friday, May 15, 2026Phase 3 overview to be presented at Trials-in-Progress session on Sunday, May 17, 2026The Phase 3 "RESCUE" registrational program remains on ...
- Analyst Upgrades
Piper Sandler Initiates Coverage On Relmada Therapeutics with Overweight Rating, Announces Price Target of $12
Piper Sandler analyst Kelsey Goodwin initiates coverage on Relmada Therapeutics with a Overweight rating and announces Price Target of $12. ...
- Analyst Upgrades
Mizuho Maintains Outperform on Relmada Therapeutics, Raises Price Target to $19
Mizuho analyst Uy Ear maintains Relmada Therapeutics with a Outperform and raises the price target from $10 to $19. ...
- GlobeNewswire
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and ...
- GlobeNewswire
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and ...
- GlobeNewswire
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time Tolerability profile remains ...
- Analyst Upgrades
LUCID CAPITAL MARKETS Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $14
LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Relmada Therapeutics with a Buy rating and announces Price Target of $14. ...
- PR Newswire
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
USA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 results in treatment-resistant depression cleared that ... ...
- Analyst Upgrades
Leerink Partners Upgrades Relmada Therapeutics to Outperform, Announces $8 Price Target
Leerink Partners analyst Andrew Berens upgrades Relmada Therapeutics from Market Perform to Outperform and announces $8 price target. ...
- GlobeNewswire
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
FDA written feedback supports: - a single-arm, open-label registrational trial in 2nd-line refractory high-grade NMIBC with CIS - a randomized vs observation single trial in intermediate-risk NMIBC in the adjuvant ...
- Analyst Upgrades
Jefferies Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $9
Jefferies analyst Farzin Haque initiates coverage on Relmada Therapeutics with a Buy rating and announces Price Target of $9. ...
- GlobeNewswire
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a sustained release ...
- Analyst Upgrades
Mizuho Upgrades Relmada Therapeutics to Outperform, Raises Price Target to $10
Mizuho analyst Uy Ear upgrades Relmada Therapeutics from Neutral to Outperform and raises the price target from $1 to $10. ...
- GlobeNewswire
Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates
Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Secured FDA alignment on key elements of Phase 3 ...